Skip to content

Tromethamine

FDA-approved product (solution, injection), marketed as Tham, Tromethamine.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Tromethamine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acidosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Solutions affecting the electrolyte balance; Other i.v. solution additives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Tromethamine, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA7.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli8.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae4.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis9.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tromethamine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effect of Spinal Ketorolac on Mechanical Hypersensitivity After a Total Hip Replacement

    NCT00621530 · start 2008-03

    Registered record
    Registry ID
    NCT00621530
    Conditions
    Hip Arthroplasty
    Interventions
    ketorolac tromethamine opthalmic solution; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2008-03
    Completion
    2013-06
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHip Arthroplasty
    Interventionketorolac tromethamine opthalmic solution; placebo
    PhasePhase 2
    Registry statusTerminated
  • Study to Assess the PK of Ketorolac Tromethamine Intranasal and to Assess the Effects of a Oxymetazoline Hydrochloride on the PK of Ketorolac Tromethamine

    NCT01363089 · start 2007-01

    Registered record
    Registry ID
    NCT01363089
    Conditions
    Assess Pharmacokinetics of Ketorolac Tromethamine Intranasal and Assess Effects of a Oxymetazoline Hydrochloride on the PK of Ketorolac Tromethamine
    Interventions
    Ketorolac tromethamine; Oxymetazoline hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-01
    Completion
    2008-02
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAssess Pharmacokinetics of Ketorolac Tromethamine Intranasal and Assess Effects of a Oxymetazoline Hydrochloride on the PK of Ketorolac Tromethamine
    InterventionKetorolac tromethamine; Oxymetazoline hydrochloride
    PhasePhase 1
    Registry statusCompleted
  • Safety and Efficacy of Multiple Doses of Intranasal Ketorolac in Postoperative Pain Following Major Abdominal Surgery

    NCT00266786 · start 2005-12

    Registered record
    Registry ID
    NCT00266786
    Conditions
    Postoperative Pain
    Interventions
    Intranasal Ketorolac Tromethamine; Intranasal Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-12
    Completion
    Not recorded
    Enrolment
    321

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Pain
    InterventionIntranasal Ketorolac Tromethamine; Intranasal Placebo
    PhasePhase 3
    Registry statusCompleted
  • A Single-dose Study of Intranasal Ketorolac in the Treatment of Pain Secondary to Dental Impaction Surgery

    NCT01356225 · start 2004-02

    Registered record
    Registry ID
    NCT01356225
    Conditions
    Pain; Dental Impaction
    Interventions
    Ketorolac tromethamine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-02
    Completion
    Not recorded
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain; Dental Impaction
    InterventionKetorolac tromethamine; Placebo
    PhasePhase 2
    Registry statusCompleted
  • The Balloon Project for Birth Induction

    NCT01255839 · start 2002-12

    Registered record
    Registry ID
    NCT01255839
    Conditions
    Induction Time; Apgar Score; Admission to Neonatal Unit; Vaginal Delivery; Caesarean Section
    Interventions
    Double Balloon; Minprostin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-12
    Completion
    2010-12
    Enrolment
    825

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInduction Time; Apgar Score; Admission to Neonatal Unit; Vaginal Delivery +1 more
    InterventionDouble Balloon; Minprostin
    PhasePhase 4
    Registry statusCompleted